News

2017 December

19
/12
Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.

2017 October

04
/10
ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has attracted Capricorn Venture Partners to conclude the second closing of its series A financing round, raising another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

2017 September

26
/09
Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. The goal of the collaboration is to deploy the Company’s proprietary Confo® technology to discover novel, small molecule therapeutic compounds acting upon two G-protein coupled receptors (GPCRs).

2017 June

16
/06
VIB, Ghent University and KU Leuven have launched a new spin-off: Aphea.Bio. This new company will develop sustainable agricultural products based on natural microorganisms to increase crop yields and to protect them against specific fungal diseases. Thanks to a successful Series A financing round and an R&D grant approved by Flanders Innovation & Entrepreneurship (VLAIO), Aphea.Bio is now backed by 9 million euros of funding, giving it a clear shot at a leading position in the fast-emerging market of biopesticides and biostimulants. Headquartered in Ghent , Belgium, Aphea.Bio will be led by CEO Dr. Isabel Vercauteren and CSO Dr. Steven Vandenabeele.